ANIX News and Press, Anixa Biosciences Inc.

Anixa Biosciences Expands Global Patent Portfolio with Australian Patent Acceptance for Breast Cancer Vaccine Technology PR Newswire Notice of Acceptance marks first Australian patent covering Anixa's breast cancer vaccine platform Continues expansion of global intellectual prop...

Anixa Biosciences and Moffitt Cancer Center Advance Ovarian Cancer CAR-T Clinical Trial to Highest Dose Level to Date PR Newswire Multiple Patients Surviving More Than One Year, Including one Beyond Two Years, with No Dose-Limiting Toxicities Observed to Date Patients in Cohort ...

Anixa Biosciences Granted First Korean Patent for its Breast Cancer Vaccine, Extending Global Protection Through 2040 PR Newswire Composition of matter patent secures exclusive protection for Anixa's breast cancer vaccine in South Korea through 2040, expanding the Company's growing...

Anixa Biosciences Reports Positive Data from Completed Breast Cancer Vaccine Phase 1 Trial and Positive Survival Observations from Ongoing CAR-T Phase 1 Trial at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium PR Newswire Breast cancer vaccine presentation...

2026-06-12 08:15:08 ET H.C. Wainwright analyst issues BUY recommendation for ANIX on June 12, 2026 10:52AM ET. The previous analyst recommendation was Buy. ANIX was trading at $2.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current ...

2026-06-12 08:15:08 ET Citigroup analyst issues BUY recommendation for ANIX on June 12, 2026 10:52AM ET. The previous analyst recommendation was Buy. ANIX was trading at $2.48 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analys...

Anixa Biosciences Announces Presentations of Two Clinical-Stage Immunotherapy Programs at New York Academy of Sciences' Frontiers in Cancer Immunotherapy Symposium PR Newswire Ovarian cancer CAR-T therapy, lira-cel, presentation to highlight positive survival observations from ongo...

LivePerson Inc. (LPSN) is expected to report $-1.02 for Q1 2026 Chewy Inc. Class A (CHWY) is expected to report $0.24 for Q1 2027 Ecopetrol S.A. American Depositary Shares (EC) is expected to report $0.6 for Q1 2026 Oxford Industries Inc. (OXM) is expected to report $1.27 for Q1 2027 ...

Medtronic plc. (MDT) is expected to report $1.54 for Q4 2026 ICON plc (ICLR) is expected to report $2.73 for Q1 2026 Cognyte Software Ltd. (CGNT) is expected to report $0.03 for Q1 2027 PVH Corp. (PVH) is expected to report $1.8 for Q1 2027 Ecopetrol S.A. American Depositary Share...

Anixa Biosciences Strengthens International Patent Protection for Ovarian Cancer Vaccine Technology with Canadian Notice of Allowance PR Newswire Allowed patent covers technology designed to elicit an AMHR2-specific immune response for the prevention or treatment of ovarian cancer ...